SCHEMBL4877448

SCHEMBL4877448

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CC(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 1.00
NR3C1 P04150 4/20 1.00
HIF1A Q16665 4/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
CYP2C19 P33261 3/20 1.00
MAPT P10636 2/20 1.00
CYP3A4 P08684 4/20 0.73
HSD17B10 Q99714 3/20 0.73
ALDH1A1 P00352 2/20 0.73
TSHR P16473 2/20 0.73
CYP2C9 P11712 1/20 0.73
SHBG P04278 4/20 0.71
PGR P06401 3/20 0.71
AR P10275 3/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
CHRM1 P11229 2/20 0.71
ABCC4 O15439 1/20 0.71
ABCB11 O95342 1/20 0.71
ESR1 P03372 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27035399 1.00 LMNA (1.00) LMNANR3C1HIF1AMEN1KMT2A
SCHEMBL15445000 1.00 LMNA (1.00) LMNANR3C1HIF1AMEN1KMT2A
SCHEMBL22761988 1.00 LMNA (1.00) LMNANR3C1HIF1AMEN1KMT2A
SCHEMBL37494 1.00 LMNA (1.00) LMNANR3C1HIF1AMEN1KMT2A
SCHEMBL13069287 1.00 LMNA (1.00) LMNANR3C1HIF1AMEN1KMT2A
Hydrochloric Acid SCHEMBL28349042 0.99 LMNA (0.98) LMNANR3C1HIF1AMEN1KMT2A
Acetic Acid SCHEMBL27624098 0.98 LMNA (0.96) LMNANR3C1HIF1AMEN1KMT2A
Acetic Acid SCHEMBL609736 0.98 LMNA (0.96) LMNANR3C1HIF1AMEN1KMT2A
Formic Acid SCHEMBL28467407 0.96 LMNA (0.92) LMNANR3C1HIF1AMEN1KMT2A
Cyclopropane Carboxylic Acid SCHEMBL27035116 0.94 LMNA (0.88) LMNANR3C1HIF1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3277285-B1 ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY UNIV CALIFORNIA (US) 2024-07-17 EP claimed
EP-3200802-B1 COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION UNIV CALIFORNIA (US) 2023-07-12 EP claimed
CN-113583074-A Novel preparation method of 6-methyl-17 alpha-hydroxyprogesterone and precursor thereof 佳尔科生物科技南通有限公司 2021-11-02 CN claimed
US-4177269-A ANTITUMOR AGENTS AKTIEBOLAGET LEO (SE) 1979-12-04 US claimed
US-4014988-A Method for treating hypermenorrhea with uterine therapeutic system ALZA CORPORATION (US) 1977-03-29 US claimed
US-20240025940-A1 NOVEL ESTERS OF MEDROXYPROGESTERONE HAFEEZ KALAK ABDUL (IN) 2024-01-25 US disclosed
US-11666584-B2 Steroidal hormones for the treatment and prevention of wave burst arrhythmia Assistance Publique—Hopitaux de Paris (FR) 2023-06-06 US disclosed
CN-113583074-A Novel preparation method of 6-methyl-17 alpha-hydroxyprogesterone and precursor thereof 佳尔科生物科技南通有限公司 2021-11-02 CN disclosed
CN-113583074-A Novel preparation method of 6-methyl-17 alpha-hydroxyprogesterone and precursor thereof 佳尔科生物科技南通有限公司 2021-11-02 CN disclosed
CN-113583074-A Novel preparation method of 6-methyl-17 alpha-hydroxyprogesterone and precursor thereof 佳尔科生物科技南通有限公司 2021-11-02 CN disclosed
US-20200352960-A1 STEROIDAL HORMONES FOR THE TREATMENT AND PREVENTION OF WAVE BURST ARRHYTHMIA ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 2020-11-12 US disclosed
EP-3188735-A1 ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY The Regents of the University of California (US) 2017-07-12 EP disclosed
US-4181721-A Depot preparations in an oily, unsaturated solution for intramuscular injection SCHERING AKTIENGESELLSCHAFT (DE) 1980-01-01 US disclosed
US-4177269-A ANTITUMOR AGENTS AKTIEBOLAGET LEO (SE) 1979-12-04 US disclosed
US-4154748-A Phosphate catalyzed acylation of steroidal tertiary alcohols THE UPJOHN COMPANY (US) 1979-05-15 US disclosed
US-4066757-A Oral contraceptive regimen ORTHO PHARMACEUTICAL CORPORATION (US) 1978-01-03 US disclosed
US-4016270-A Method for treating dysmenorrhea with a uterine therapeutic system ALZA CORPORATION (US) 1977-04-05 US disclosed
US-3993057-A Intrauterine device that bioerodes in response to the environment of the uterus and method of using ALZA CORPORATION (US) 1976-11-23 US disclosed
US-3971367-A Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape ALZA CORPORATION (US) 1976-07-27 US disclosed
US-3935860-A Intrauterine device with restrictor for maintaining device in uterine cavity ALZA CORPORATION (US) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352960-A1 STEROIDAL HORMONES FOR THE TREATMENT AND PREVENTION OF WAVE BURST ARRHYTHMIA SHBG, NR5A1, HSD17B11 LMNA 626/4885NR3C1 52/4885HIF1A 2048/4885
US-20240025940-A1 NOVEL ESTERS OF MEDROXYPROGESTERONE HSD17B11, CYP19A1, CYP17A1 LMNA 4253/4885NR3C1 90/4885HIF1A 1860/4885
US-11666584-B2 Steroidal hormones for the treatment and prevention of wave burst arrhythmia SHBG, NR5A1, HSD17B11 LMNA 626/4885NR3C1 52/4885HIF1A 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.